GSS Stock Overview
Operates as a molecular diagnostic (MDx) company in Australia, the Asia Pacific, the Americas, Europe, the Middle East, Israel, and Africa.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Genetic Signatures Limited Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | AU$0.75 |
52 Week High | AU$0.77 |
52 Week Low | AU$0.40 |
Beta | 0.14 |
1 Month Change | 8.70% |
3 Month Change | 31.58% |
1 Year Change | 29.31% |
3 Year Change | -38.52% |
5 Year Change | -28.57% |
Change since IPO | 50.00% |
Recent News & Updates
Recent updates
Shareholder Returns
GSS | AU Life Sciences | AU Market | |
---|---|---|---|
7D | 2.7% | -1.9% | -0.3% |
1Y | 29.3% | -8.3% | 8.5% |
Return vs Industry: GSS exceeded the Australian Life Sciences industry which returned -8.3% over the past year.
Return vs Market: GSS exceeded the Australian Market which returned 8.5% over the past year.
Price Volatility
GSS volatility | |
---|---|
GSS Average Weekly Movement | 8.2% |
Life Sciences Industry Average Movement | 10.5% |
Market Average Movement | 8.8% |
10% most volatile stocks in AU Market | 16.9% |
10% least volatile stocks in AU Market | 3.3% |
Stable Share Price: GSS's share price has been volatile over the past 3 months.
Volatility Over Time: GSS's weekly volatility (8%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2001 | n/a | Neil Gunn | www.geneticsignatures.com |
Genetic Signatures Limited operates as a molecular diagnostic (MDx) company in Australia, the Asia Pacific, the Americas, Europe, the Middle East, Israel, and Africa. It designs and manufactures a suite of real-time polymerase chain reaction-based products for detection of infectious diseases under the EasyScreen brand name. The company also provides MDx 3Base platform technology that enables hospital and pathology laboratories to screen for a range of infectious pathogens.
Genetic Signatures Limited Fundamentals Summary
GSS fundamental statistics | |
---|---|
Market cap | AU$136.16m |
Earnings (TTM) | -AU$18.04m |
Revenue (TTM) | AU$15.99m |
8.5x
P/S Ratio-7.5x
P/E RatioIs GSS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
GSS income statement (TTM) | |
---|---|
Revenue | AU$15.99m |
Cost of Revenue | AU$9.79m |
Gross Profit | AU$6.20m |
Other Expenses | AU$24.24m |
Earnings | -AU$18.04m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -0.097 |
Gross Margin | 38.79% |
Net Profit Margin | -112.83% |
Debt/Equity Ratio | 0% |
How did GSS perform over the long term?
See historical performance and comparison